GenArraytion, Inc. Announces MultiFLEX Molecular Assay Optimization for the Joint Program Executive Office for Chemical and Biological Defense (JPEO CBD) in Support of the Global Biosurveillance Technology Initiative (GBTI)

November 9, 2015

Rockville, MD – GenArraytion, Inc., is pleased to announce the successful completion of a project for the optimization of five separate MultiFLEX molecular assay panels for the identification of over 65 infectious disease targets of world-wide US military concern.  The project was in support of the Joint Program Executive Office for Chemical and Biological Defense’s (JPEO CBD) Global Biosurveillance Technology Initiative (GBTI), which is working to improve the biosurveillance capacity for the Department of Defense to systematically deploy an infectious disease testing capability to improve detection capacity while connecting these labs to a networked analytics and communication hub, JPEO provides worldwide users with timely, actionable, and operationally valuable information enabling a more effective response to a health crisis anywhere in the world.  The MultiFLEX molecular assays are infectious disease panels with 12 to 20 individual molecular targets for fever causing and vector born microorganisms of military concern across the globe. The tests are designed to work on the Luminex MagPix instruments which have been distributed to the military area labs around the world.

 The work was conducted jointly with Battelle and was sponsored by the Defense Technical Information Center. ATTN: DTIC-AI, B723 John J. Kingman Rd., Ste 0944, Fort Belvoir, VA 22060-6218.

For more information, please contact:

Katy Delaney at (614) 424-7208 or at delaneyk@battelle.org or contact T.R. Massey at (614) 424-5544 or at masseytr@battelle.org.

Based in Rockville, MD, GenArraytion, Inc. is a privately held, Veteran owned, small business dedicated to the development and commercialization of multiplexed molecular assays for infectious diseases.  GenArraytion is dedicated to improving healthcare through the development and distribution of treatment-guiding molecular assays on a variety of platforms.  GenArraytion develops molecular assays for biodefense applications, infectious disease markets, environmental and forensic applications, and veterinary markets.  For more information, visit www.genarraytion.com.

For more information, please contact:

Robert Vereen, Operations Analyst, GenArraytion Inc. 240-453-9064

rvereen@genarraytion.com  or visit www.genarraytion.com